A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
about
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsImmunotherapy in metastatic prostate cancerTwelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentSipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.Immune Checkpoint Therapies in Prostate Cancer.Immune Therapy for Prostate Cancer.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.TCR diversity - a universal cancer immunotherapy biomarker?The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.
P2860
Q26747699-6977D7BB-BE64-41F7-9072-79DA54D7BC89Q26750672-52313354-3934-4DE2-B8DB-ECED20AF57B5Q28072081-B19E5D51-2659-4D95-9EA6-58636E94584EQ30846001-31C25F07-C119-429D-BFA5-BFD257A012A4Q33718182-683B35DC-EB78-4572-A50B-F403F50F0DBDQ34787165-84B63F43-2E1A-4FBB-9D5C-F86B7B843CCFQ37518336-DD4963A5-F40E-4126-8348-19A286C76063Q38508313-B0417FA9-301A-4F73-85D2-82103DAED101Q38816839-4BA22FA6-F4EF-4F73-A637-4A029664627CQ38982667-93921D13-916F-4DCB-A5A2-36DD16B4FB9DQ38994718-6A05EC54-C22D-4969-93D9-9804656E0022Q41869616-9E40845D-D876-4A93-91B4-EAF34E96CAFFQ42368649-F82D18CA-BD4F-4BF0-B5DF-8959CBA56CFBQ49545290-0692237B-BEB2-4A58-8398-5E1D79FEE28F
P2860
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@ast
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@en
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@nl
type
label
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@ast
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@en
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@nl
prefLabel
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@ast
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@en
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@nl
P2093
P2860
P1476
A transient increase in eosino ...... ncer who receive sipuleucel-T.
@en
P2093
Celestia S Higano
Douglas G McNeel
Eric J Small
Mark H Wener
Nadeem A Sheikh
Robert B Sims
Robert Dreicer
Thomas A Gardner
Todd DeVries
P2860
P304
P356
10.1158/2326-6066.CIR-14-0073
P577
2014-09-04T00:00:00Z